Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-08-28

CRISPR Therapeutics AG

Gene-editing biotech developing CRISPR-, siRNA-, and cell-based medicines, with shared economics on CASGEVY and a broader wholly owned pipeline.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, broader franchise still pending

The company has already cleared the first major trust hurdle in gene editing. The next five years depend on converting that credibility into steadier CASGEVY economics and at least one more real franchise.

Analysis

Thesis

CRISPR Therapeutics already cleared the first trust gate with an approved CRISPR therapy; if CASGEVY scales into steadier economics and one or two owned assets become commercially credible by 2031, the stock can rerate from cash-backed platform optionality into a multi-franchise gene-medicine company.

Last Economy Alignment

AI lowers discovery and development friction, but CRISPR captures value mainly through regulated trust, manufacturing know-how, and clinical evidence rather than cheap software.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

The upside does not require every program to work. A cleaner CASGEVY profit stream, one successful owned cardiometabolic asset, and one additional credible franchise would change how investors value the business: less as cash plus experiments, more as a repeatable genetic-medicines platform. That supports a solid rerating, but not a priced-for-perfection outcome.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not funding but proof conversion. CRISPR must turn one approved therapy into repeatable economics while showing that owned assets can survive safety, durability, reimbursement, and manufacturing filters. Vertex dependence and treatment-center bottlenecks matter almost as much as the science.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On August 28, 2026, CRISPR disclosed the CTX310 durability dataset at ESC, moving a key in vivo proof point from anticipated to observed.
The market now has one less purely hypothetical gate in cardiometabolic editing, but commercial timing is still several steps away.
No near-term balance-sheet shock emerged around the latest update, so the debate shifts back to platform breadth and revenue conversion.

Thesis update

The core thesis is intact, but confidence improved modestly because CTX310 moved from promise to fresh human durability evidence.

Forecast update

Recent data slightly improved the quality of the upside path and reduced one important proof discount.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.53

They own valuable gene-editing know-how, regulated manufacturing capability, and a growing clinical evidence base, so AI should help them design and execute faster. But biology, reimbursement, and partner control still decide how much of that value becomes profit.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$87.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research